IL1B and metabolic dysfunction-associated steatotic liver disease: Interestingly, the NAFLD + AT + RSV group exhibited a more pronounced decrease in IL‐1β, IL‐6, and TNF‐α expression (4.09‐fold, 26.90‐fold, and 5.47‐fold, respectively) than the other treatment groups (p = 0.001, < 0.0001, and 0.003, respectively; Figure 4A–C).